+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 14 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating Risvutatug rezetecan Ris-Rez, a new medicine targeting specific proteins B7-H3 on cancer cells, in people with relapsed small cell lung cancer SCLC. The study compares Ris-Rez with the standard treatment topotecan to see if Ris-Rez can shrink tumors or make them disappear and if it helps participants live longer. It also examines the safety and side effects of both treatments to better understand their impact. Participants with relapsed SCLC will be randomly assigned to receive either Ris-Rez or topotecan. Both treatments will be administered according to standard protocols, with Ris-Rez provided as a biological therapy and topotecan as a drug treatment. The study is open-label, meaning both participants and researchers know which treatment is given. During the study, participants will be monitored through various assessments including survival time, tumor response, symptom changes, brain progression, and quality of life measures. Safety will be closely tracked through adverse event reports, laboratory tests, heart function evaluations, and immune response monitoring. The main outcome focuses on overall survival, with follow-up extending up to approximately 113 weeks to capture long-term effects and responses.

Age: 18Years +All GendersPhase 3
144 locations
A

Actively Recruiting

Researchers are evaluating the effectiveness and safety of a new drug called GSK3862995B in adults with bronchiectasis, a chronic lung disease. This Phase 2 study also examines how the body processes the drug and checks for any immune reactions. Participants will be randomly assigned to receive one of two doses of GSK3862995B or a placebo to compare their effects on bronchiectasis. Participants will receive either Dose Level 1 or Dose Level 2 of GSK3862995B, or a matching placebo. The study uses a double-blind, randomized design, meaning neither participants nor researchers know who gets which treatment. The treatment period lasts up to 48 weeks, during which participants receive repeated doses. The study also includes assessments up to 72 weeks to monitor safety and immune responses. During the trial, participants will undergo evaluations including lung function tests, quality-of-life questionnaires, and monitoring of respiratory symptoms. Researchers will track the number of lung exacerbations, serious adverse events, laboratory tests, vital signs, and electrocardiograms to assess safety and effectiveness. Participants will be involved in regular visits and assessments throughout the treatment and follow-up periods, lasting up to about 72 weeks in total.

Age: 18Years - 85YearsAll GendersPhase 2
134 locations
R

Actively Recruiting

Researchers are evaluating mocertatug rezetecan Mo-Rez in treating endometrial cancer EC compared to standard chemotherapy options. The study aims to understand how well Mo-Rez works and how safe and tolerable it is for participants, including comparing side effects between Mo-Rez and standard treatments. This is a phase 3 randomized, open-label study focusing on treatment after prior platinum-based chemotherapy and immunotherapy. Participants will receive either mocertatug rezetecan or standard of care chemotherapy, which includes paclitaxel or doxorubicin, based on the investigators choice. The study uses a parallel design to compare these treatments directly. Treatment and assessments will continue for up to about 97 weeks for primary outcomes, with longer follow-up for secondary outcomes up to approximately 156 weeks. Throughout the study, participants will undergo multiple evaluations, including tumor response assessments by blinded independent central review and investigator assessments. Researchers will monitor progression-free survival, overall survival, treatment side effects, and quality of life using specialized questionnaires. Laboratory tests, vital signs, ECGs, and antibody measurements against the study drug will also be performed. The total participation time may extend over several years to capture long-term outcomes and safety data.

Age: 18Years +FEMALEPhase 3
56 locations
R

Actively Recruiting

Researchers are studying Mocertatug rezetecan Mo-Rez to see how it works in treating ovarian cancer that does not respond well to platinum-based therapies. This Phase 3 trial compares Mo-Rez to standard chemotherapy treatments while evaluating its safety, tolerability, and side effects. The study is sponsored by GlaxoSmithKline and focuses on platinum-resistant ovarian cancer, including specific tumor types confirmed by tissue testing. Participants will be randomly assigned to receive either Mo-Rez or one of several standard chemotherapy options chosen by their doctor, including Paclitaxel, Pembrolizumab with or without Bevacizumab, Pegylated liposomal doxorubicin PLD, Topotecan, or Gemcitabine. The treatments will be given according to standard administration methods, and participants may continue in the study for up to approximately 212 weeks to evaluate long-term outcomes. Throughout the study, participants will undergo regular assessments including tumor scans to measure disease progression and response, blood tests, and quality-of-life questionnaires. Researchers will monitor survival rates, side effects, vital signs, laboratory values, and immune responses to the drug. Safety monitoring and patient-reported outcomes will continue for the full duration of participation, which may last over four years.

Age: 18Years +FEMALEPhase 3
22 locations
E

Actively Recruiting

Researchers are evaluating depemokimab as a treatment for adults with moderate to severe chronic obstructive pulmonary disease COPD who have type 2 inflammation and uncontrolled symptoms. This Phase 3 study aims to assess the effectiveness and safety of depemokimab when added to standard care for these patients. The focus is on reducing COPD exacerbations and improving respiratory health. Participants will be randomly assigned to receive either depemokimab or a placebo along with their usual COPD treatments. Depemokimab is given as a sterile liquid formulation, and the study compares its effects against placebo over a period of up to 104 weeks. Both groups continue their optimized inhaler therapy during the trial. During the study, participants will undergo regular assessments including lung function tests, symptom questionnaires like the COPD assessment test CAT, and monitoring of exacerbations. Researchers will measure outcomes such as the rate of moderate or severe exacerbations annually and changes in respiratory symptoms. Safety and overall health are closely followed throughout the two-year treatment period.

Age: 40Years - 80YearsAll GendersPhase 3
281 locations
E

Actively Recruiting

Researchers are evaluating the effects of CSL787, a human normal immunoglobulin G IgG inhalation solution, in adults with Non-cystic Fibrosis Bronchiectasis NCFB. This proof-of-concept phase 2b study is randomized, double-blind, placebo-controlled, and aims to explore the efficacy, safety, and tolerability of two different doses of nebulized CSL787 compared with placebo over a 52-week period. The main goal is to understand how CSL787 affects the time to the first exacerbation in participants with NCFB. Participants will be randomly assigned to receive either a high dose or a low dose of CSL787 inhaled once daily via nebulizer, or a matching placebo, for up to 52 weeks. The nebulizer device used is CE-marked. The study includes three arms high dose CSL787, low dose CSL787, and placebo. The treatment period lasts for 52 weeks, during which participants will receive daily inhalation treatments corresponding to their assigned group. During the study, participants will be closely monitored with various assessments including lung function tests, sputum collection for bacterial analysis, quality of life questionnaires focused on respiratory symptoms, and recording of any exacerbations or adverse events. Researchers will measure the time to first exacerbation, number of exacerbations, changes in respiratory symptoms, and safety outcomes up to 56 weeks. Participation involves regular visits and evaluations to assess treatment effects and monitor safety throughout the study duration.

Age: 18Years - 85YearsAll GendersPhase 2
13 locations
D

Actively Recruiting

Healthy Volunteer

Researchers are developing a new blood test to detect colorectal adenomas and cancer early. Colorectal cancer is a major health concern worldwide, ranking third in diagnosis and second in death rates. Existing screening methods like fecal immunochemical tests can detect cancer but not precancerous lesions called adenomas. This trial focuses on creating a more sensitive and specific non-invasive test by combining advanced machine learning with biological analyses to improve early detection of both adenomas and colorectal cancer.

Age: 18Years +All Genders
6 locations
N

Actively Recruiting

Healthy Volunteer

Early-onset colorectal cancer EOCRC, defined as colorectal cancer diagnosed before age 50, is rising sharply among young adults and is a leading cause of cancer-related death in this group. This research aims to develop a non-invasive blood test using microRNA and advanced machine learning to detect EOCRC earlier and more effectively than current screening methods, which are often invasive and have low participation rates in younger populations. The study focuses on analyzing circulating cell-free microRNAs and exosomal microRNAs from blood samples to create a combined diagnostic panel. This approach seeks to improve detection accuracy by leveraging the sensitivity of cell-free microRNAs and the specificity of exosomal microRNAs. The research is conducted in three phases sequencing RNA samples, developing and training detection panels using machine learning, and validating the test in an independent group of participants including EOCRC patients and cancer-free controls. Participants contribute blood samples for molecular testing and data analysis. Researchers will assess the tests sensitivity, specificity, and overall accuracy over approximately one year. The study aims to produce a cost-effective and patient-friendly screening tool that could enhance early detection of EOCRC, improve patient care, and reduce mortality rates.

Age: 18Years - 50YearsAll Genders
13 locations
E

Actively Recruiting

Researchers are studying the use of depemokimab as an additional treatment for adults aged 40 to 75 with moderate to severe Chronic Obstructive Pulmonary Disorder COPD who also have type 2 inflammation. The goal is to evaluate the effectiveness and safety of starting depemokimab early alongside the standard care these patients already receive. This study is a Phase 3 trial designed to better understand how depemokimab might help reduce COPD exacerbations in this specific group. Participants will be randomly assigned to receive either depemokimab or a matching placebo, both given in combination with their existing standard treatments for COPD. The treatment period lasts up to 156 weeks about 3 years, during which the study compares the rate of moderate to severe COPD flare-ups between the two groups. This trial uses a parallel design with quadruple masking to maintain objectivity and includes ongoing standard care throughout. Throughout the study, participants will have regular evaluations to monitor their lung function, symptoms, and quality of life using questionnaires like the St. Georges Respiratory Questionnaire and the Evaluating Respiratory Symptoms E-RS for COPD. The main outcome measured is the annual rate of moderate or severe exacerbations over the study period. Safety and response to treatment will be closely observed, with follow-up continuing until the primary completion date in April 2029 and final study completion in June 2029.

Age: 40Years - 75YearsAll GendersPhase 3
121 locations
R

Actively Recruiting

Researchers are evaluating the safety and clinical effects of Awiqli in people with diabetes mellitus in Japan during routine medical care. This observational study aims to collect real-world data on the use of Awiqli over a one-year period. The study focuses on participants with any type of diabetes who are prescribed Awiqli independently of the study. Participants will receive commercially available Awiqli as directed by their treating doctors according to standard clinical practice. There is no experimental treatment assignment as this is a non-interventional study. The study observes the use of Awiqli over 52 weeks without altering usual care. During the study, participants will be monitored for adverse reactions and events, serious adverse events, and changes in diabetes-related clinical parameters including HbA1c, fasting plasma glucose, and diabetes therapy-related quality of life. Data will be collected from baseline through week 52. The total participation time lasts about one year.

All AgesAll Genders
116 locations

1-10 of 14

1